33 results about "Septic shock" patented technology

本发明实施例公开了一种基于蛋白质组学的脓毒症休克患者液体管理策略预测方法。所述方法包括：收集脓毒症休克患者的血浆样本，检测蛋白质标志物的表达水平，所述蛋白质标志物为GAL、NFASC、MICB_MICA、MAP2K6、JCHAIN和CSF3的组合；基于亚组识别模型计算效益得分，获得脓毒症休克患者的液体管理策略结果。本发明通过收集脓毒症休克患者的临床数据和蛋白质表达数据，采用LASSO回归分析，构建基于上述蛋白质标志物的亚组识别模型，进而获得效益评分，基于效益评分能预测患者液体管理策略方案的适用性，为脓毒症休克患者的液体治疗提供了可靠的方案，实现个体化和精准的液体治疗，在临床具有较好的应用前景。

The present invention provides a therapeutic agent for sepsis and / or septic shock, comprising, as an active ingredient, a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for sepsis and / or septic shock, the method comprising selecting a compound capable of suppressing phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for colitis, comprising, as an active ingredient, a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for colitis, the method comprising selecting a compound capable of promoting phosphorylation of threonine at position 749 in human STAT1; a therapeutic agent for systemic lupus erythematosus, comprising, as an active ingredient, a compound capable of inhibiting human STAT1; and a method for screening for a candidate compound serving as an active ingredient of a therapeutic agent for systemic lupus erythematosus, the method comprising selecting a compound capable of inhibiting human STAT1.

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the disclosure relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

The invention relates to the technical field of medicines, in particular to application of AV-412. The invention relates to an application of AV-412 in preparation of an NLRP3 inflammasome inhibitor. The invention discloses application of AV-412 in preparation of a medicine for treating infectious shock. The invention discloses application of AV-412 in preparation of a medicine for treating acute liver injury. The invention discloses application of AV-412 in preparation of a medicine for treating acute peritonitis. The invention provides a new choice for medicines for preventing or treating NLRP3 inflammasome related diseases, and also provides a new medicine with treatment potential for infectious shock, acute liver injury and acute peritonitis.

The invention relates to the technical field of medicines, in particular to application of garcinia cambogia ketone C. The invention relates to an application of gamboge C in preparation of an NLRP3 inflammasome inhibitor. The invention relates to an application of garcinia cambogia ketone C in preparation of a medicine for treating infectious shock. The invention relates to an application of garcinia flavone C in preparation of a medicine for treating acute liver injury. The invention relates to an application of garcinia flavone C in preparation of a medicine for treating acute peritonitis. The invention provides a new choice for medicines for preventing or treating NLRP3 inflammasome related diseases, and also provides a new medicine with treatment potential for infectious shock, acute liver injury and acute peritonitis.

Methods of using lipid binding protein molecules to treat a subject having or at risk of one or more conditions, such as sepsis (e.g., septic shock).

The application provides a blood stream infection related septic shock multi-modal fusion prediction method and system, belonging to the field of intelligent medical treatment, and solving the problems of long time consumption, insufficient sensitivity and insufficient multi-modal information analysis capability in blood stream infection related septic shock. The method comprises: acquiring multi-modal clinical data of a target patient suspected of blood stream infection within a preset observation time window to obtain a multi-modal multi-scale feature sequence formed by combining each modality spatiotemporal feature vector sequence; inputting the multi-modal multi-scale feature sequence into a time sequence encoding network based on a multi-head attention mechanism to obtain an aligned multi-modal time sequence representation sequence; setting a learnable modality weight parameter for each modality, and updating the learnable modality weight parameter, the encoder and the time sequence encoding network through a task loss function according to the label of whether blood stream infection related septic shock occurs or not in the training process to obtain a multi-modal fusion model for prediction.

The present application provides a kind of fused ring compound and its preparation and use. Specifically, the structure of the compound is as shown in formula (I), the compound of formula (I) or its pharmaceutically acceptable salt, for increasing the activity of liver-type phosphofructokinase, can be used for treating diseases related to liver-type phosphofructokinase activity, such as cancer, diabetes, sepsis and septic shock.I.

The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

Microvascular leak plays a critical role in the outcome of sepsis. Counteracting vascular leakage has recently raised a huge interest in the field but therapeutic targets and translation studies are crucially lacking. The inventors hypothesized that ANGPTL4 might counteract lipopolysaccharide-induced vascular hyperpermeability. Mechanistically, the inventors show that the C-terminal fragment of ANGPTL4 recapitulates full-length ANGPTL4 inhibition of vascular permeability by stabilizing endothelial cell adherent junctions whereas the N-terminus has no such effect. The inventors further demonstrate that giving human recombinant c- ANGPTL4 to mice prevents microvascular leak and mortality induced by LPS. In humans, the inventors describe the association between ANGPTL4 plasma level at time of inclusion and 90- day mortality in sepsis or septic shock patients French and European Outcome Registry in Intensive Care Units (FROG-ICU). In conclusion, the inventors demonstrate that suppressing vascular permeability by c-ANGPTL4 could be a novel therapeutic for the treatment of sepsis capillary leak syndrome. Either alone or in combination with existing drugs, c-ANGPTL4 could contribute to the reduction of mortality in patients with shock states.

The invention belongs to the technical field of medicines, and particularly relates to a microneedle patch for disguising a macrophage cell membrane and a preparation method of the microneedle patch. Degradable high polymer material nano-particles camouflaged by the macrophage membrane are embedded in a microneedle array of the microneedle patch camouflaged by the macrophage membrane, and the degradable high polymer material nano-particles camouflaged by the macrophage membrane are wrapped with gambogic acid and oleic acid functionalized cerium dioxide nano-particles. Nanoparticles of the microneedle patch jointly load gambogic acid and oleic acid functionalized cerium dioxide, through microneedle transdermal drug delivery, active targeting of the drug to the liver is achieved by using natural inflammatory taxis of a macrophage membrane, the anti-inflammatory effect of gambogic acid and the anti-oxidation effect of cerium dioxide are synergistically exerted, polarization of macrophages is adjusted, and the anti-inflammatory effect of the drug on the liver is achieved. Therefore, the liver injury caused by the septic shock is treated.

This invention relates to the field of medical artificial intelligence technology and discloses a method for predicting the resuscitation status of patients with septic shock. The method includes: acquiring state parameters of the patient with septic shock; preprocessing the acquired state parameters to obtain input parameters; obtaining training data based on a critical care database; training a prediction model using the training data; inputting the input parameters into the trained prediction model to obtain a first prediction probability; and performing binary classification on the first prediction probability to obtain a final prediction result. The state parameters include target parameters, which include multiple variables such as mean arterial pressure, arterial blood lactate, base excess, pH, bicarbonate, and anion gap. This method and system for predicting the resuscitation status of patients with septic shock can prospectively output the overall probability of achieving resuscitation targets at the 6th hour using conventionally available multidimensional clinical information within 0-2 hours after admission to the ICU.

The invention relates to novel heteroaryl compounds of Formula (I), and pharmaceutically acceptable salts thereof; and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.

The invention relates to a method for the prediction of an increase of dipeptidyl peptidase 3 (DPP3) in a critically ill patient. In particular, the method comprises providing a sample from said patient, determining a level of Dipeptidyl peptidase 3 (DPP3) in said sample, comparing said level to a pre-determined threshold, wherein the level of DPP3 in said sample is indicative of an increase of DPP3 if said level of DPP3 is above a pre-determined threshold level, which is in the range between 22 and 40 ng / ml. Furthermore, the invention also relates to a method for the prevention of a DPP3 increase in a critical ill patient, wherein a DPP3 inhibitor is administered to the patient if the level of DPP3 is above a threshold between 40 ng / ml and 22 ng / ml and said DPP3 inhibitor is an anti-DPP3-antibody and / or and anti-DPP3-antibody fragment and / or anti-DPP3 scaffold. Moreover, the invention also relates to a DPP3 inhibitor for use in the prevention of a DPP3 increase in a critical ill patient.

Use of anisodamine hydrobromide in the preparation of a drug for treating sepsis and / or septic shock. Anisodamine hydrobromide can ameliorate CLP-induced changes in vital signs of rats, improve the morphology of lung tissue, regulate related target proteins, and produce a good therapeutic effect on sepsis and / or septic shock.

The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

he disclosure relates generally to the field of sepsis. The disclosure also relates to anti-PAL antibodies, and to methods of using these anti-PAL antibodies to treat sepsis or septic shock. Methods for treating certain immunosuppressed states associated with recovery from sepsis using the anti-PAL antibodies are also disclosed.

The present invention relates to the diagnosis of sepsis and / or septic shock and monitoring the extent thereof; the early assessment of the risk of developing sepsis and / or septic shock; the prediction or determination or monitoring of the need for a therapy or intervention in a subject. The present invention relates to a method which comprises determining the level of a biomarker selected from the group consisting of ADM-Gly, PAMP, MR-proADM and CT-proADM or a fragment of at least five amino acids thereof, or the total ADM, or the ratio of the level of said biomarker to the level of ADM-Nffz, in a sample of a subject, and wherein the level of said biomarker or said ratio is indicative of sepsis and / or septic shock or the extent of sepsis and / or septic shock, or is predictive of an increased risk of developing sepsis and / or septic shock, or is indicative of the need for a therapy or intervention in said subject for sepsis and / or septic shock.

The invention relates to organic chemistry, pharmacology and medicine and concerns novel antiviral peptides. The claimed peptides are characterized by a high level of antiviral activity and show promise for use in the treatment of infectious diseases caused by a viral infection, inter alia, diseases caused by SARS-CoV-2 such as, for example, a simple infection (such as a fever, a cough and / or a sore throat), pneumonia, acute or severe respiratory infection, hypoxic respiratory failure, acute respiratory distress syndrome, sepsis or septic shock and, in particular, COVID-19.

The invention relates to the technical field of medicines, in particular to application of anisodamine hydrobromide. The invention provides new application of anisodamine hydrobromide, and researches show that anisodamine hydrobromide can improve rat vital sign changes caused by CLP, improve lung tissue morphology and regulate related target proteins, so that the anisodamine hydrobromide has a good treatment effect on sepsis and / or septic shock.

The invention relates to application of platelet-derived protein in differential diagnosis of sepsis and sepsis shock. Specifically, the invention proposes that vesicle-related membrane protein 8 (VAMP8) in platelets and various differential proteins including VAMP2, SNAP23 and STX16 are used as key biomarkers for the first time to distinguish between sepsis patients and septic shock patients. Compared with the prior art, by detecting the expression levels of the specific proteins in the platelets, the severity of diseases can be distinguished more accurately and earlier on the molecular level, the diagnosis specificity is remarkably improved, and a new effective means is provided for clinical early warning and accurate intervention. The invention also provides a detection kit containing related reagents and a corresponding differential diagnosis method.

A method (100) for training a hemodynamic instability cause classification model to classify a patient's determined likelihood of future hemodynamic instability as caused by one or more of cardiogenic shock, septic shock, and hypovolemic shock, the method comprising: (i) receiving (120) a preliminary cause classification model training dataset; (ii) analyzing (130) the received dataset to classify each patient as likely to be hemodynamically unstable; (iii) analyzing (140) the received patient information by an outlier detection model to determine whether that patient's hemodynamic instability is likely to be cardiogenic shock, septic shock, hypovolemic shock, or an outlier; (iv) generating (150) a final cause classification model training dataset by removing each of the patients determined as being an outlier; and (v) training (160) the hemodynamic instability cause classification model to classify a cause of the patient's determined likelihood of future hemodynamic instability.

The present invention relates to an antimicrobial adjuvant containing a biphenyl derivative compound as an active ingredient, and a technology of various uses thereof. The compound of the present invention reduces the dosage of polymyxin antibiotics, which are administered to inhibit the proliferation of gram-negative bacteria, by enhancing the sensitivity of the gram-negative bacteria with respect to the polymyxin antibiotics, is concomitantly administered with the polymyxin antibiotics to show gram-negative bacteria growth inhibitory and killing effects, may notably reduce side effects such as nephrotoxicity, and may prevent or treat sepsis and septic shock due to antibiotic overuse.

To provide an in vitro method for assessing the risk of developing sepsis, systemic inflammatory response syndrome (SIRS), septic shock, or multiple organ dysfunction syndrome (MODS) in a subject. Also provided are pharmaceutical compositions for the treatment of sepsis, SIRS, septic shock or MODS in a subject.SOLUTION: Determining or having determined the presence or absence of i) a PCSK9 variant nucleic acid sequence encoding a Pro-protein convertase subtilisin / kexin type 9 (Arg46Leu) PCSK9; and ii) a low-density-lipoprotein receptor (LDLR) variant nucleic acid sequence comprising a single nucleotide polymorphism rs6511720 in a biological sample obtained from the subject, wherein the subject is a PCSK9 reference and being a LDLR reference indicates that the subject has an increased risk of developing SIRS / MODS.SELECTED DRAWING: None

The present disclosure provides methods of treating subjects having sepsis, SIRS, septic shock, and / or MODS, methods of identifying subjects having an increased risk of developing sepsis, SIRS, septic shock, and / or MODS, and methods of detecting Proprotein Convertase Subtilisin / Kexin Type 9 (PCSK9) and / or Low Density Lipoprotein Receptor (LDLR) variant nucleic acid molecules and variant polypeptides.

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the disclosure relates to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.

Provided herein is technology relating to treating septic shock and particularly, but not exclusively, to methods and systems for identifying sepsis patients most likely to benefit from L-carnitine treatment.

Phytosphingosine derivatives suitable as adjuvants in immune stimulation, pharmaceutical compositions comprising such compounds and the medical use of the compounds and / or compositions in therapeutic or prophylactic methods of immune stimulation in a subject, and for use in the treatment of a disease, for which stimulation of an immune response in a subject produces a therapeutic benefit. The phytosphingosine derivative may also be used as adjuvants in vaccinating a subject. The phytosphingosine derivative may also be used in stimulating antibody production, stimulating an immune response against infection, stimulating an immune response against a cancer, or preventing and / or treating septic shock. Methods for the manufacture of the derivatives comprising an Ugi-4-component reaction (Ugi-4CR) is also disclosed.